Testing a Medication for Treating Chronic Fatigue in Patients Visiting Psychiatry Clinics in Shiraz

Investigating the efficacy of Lisdexamfetamine Dimesylate in treatment of chronic fatigue syndrome in psychiatric clinics of Shiraz city

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20250428065515N1

Enrollment

Registered

2025-08-25

Start date

2025-08-23

Completion date

Unknown

Last updated

2025-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Fatigue Syndrome (CFS). Postviral fatigue syndrome

Interventions

Intervention Group:This is an interventional study in which Lisdexamfetamine dimesylate is administered to patients diagnosed with Chronic Fatigue Syndrome (CFS) for a period of three months. The stud

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: All patients diagnosed with Chronic Fatigue Syndrome by the treating physician Participants must be 18 years of age or older.

Exclusion criteria

Exclusion criteria: Patients with severe psychiatric disorders, epilepsy, or other serious medical conditions. Patients who do not adhere to prescribed medication. Patients who are taking multiple similar medications simultaneously.

Design outcomes

Primary

Measure	Time frame
Chronic Fatigue Syndrome score in the Jason Questionnaire. Timepoint: Before intervention and 3 months after intervention. Method of measurement: Jason Chronic Fatigue Syndrome Questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMahsa Taghavi

Islamic Azad University of Kazerun

Dr_mahsataghavi@yahoo.com+98 71 3634 1771

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026